Leqembi and Kisunla represent two different approaches to slowing early Alzheimer’s disease progression, but they differ significantly in how often patients must receive infusions and how quickly they reach therapeutic dose. Leqembi requires bi-weekly intravenous infusions for 18 months, while Kisunla can reach therapeutic levels with fewer initial infusions and potentially transitions to monthly maintenance dosing—a substantial difference for patients managing their treatment schedule.
Both carry risks of amyloid-related imaging abnormalities (ARIA), particularly brain microhemorrhages and swelling, but the drugs’ different mechanisms and dosing profiles mean these risks manifest differently in individual patients. Consider a 68-year-old patient with mild cognitive impairment caused by Alzheimer’s pathology: starting Leqembi means committing to a clinic visit every two weeks for 18 months, with ongoing MRI scans to monitor for asymptomatic brain changes. The same patient starting Kisunla might complete induction dosing in six to eight weeks, then shift to monthly infusions—reducing the treatment burden significantly, though still requiring long-term monitoring for the same safety concerns.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How Do Infusion Schedules Differ Between Leqembi and Kisunla?
- What Is the Complete Treatment Timeline and Monitoring Duration?
- Understanding ARIA (Amyloid-Related Imaging Abnormalities) and Risk Profiles
- Who Is Eligible to Receive Each Drug and What Testing Is Required?
- Managing Infusion Reactions and Required Safety Monitoring
- Insurance, Cost, and Access Barriers in Practice
- Questions Every Patient Should Discuss With Their Doctor Before Starting Treatment
How Do Infusion Schedules Differ Between Leqembi and Kisunla?
Leqembi follows a consistent bi-weekly infusion schedule throughout its 18-month treatment window. Each infusion lasts approximately one hour, and patients must travel to an infusion center to receive it—meaning roughly 36 separate clinic visits over the course of treatment. This regular cadence provides consistent drug exposure but creates a substantial logistical commitment, particularly for older patients who may rely on caregivers for transportation or have mobility limitations. Kisunla operates on an accelerated loading phase followed by maintenance dosing.
Patients typically receive four weekly or bi-weekly infusions to reach therapeutic levels, sometimes followed by additional weekly infusions for several weeks, then transition to monthly maintenance—reducing the total number of infusions required in the first several months. The exact schedule can be individualized based on body weight and clinical considerations, offering flexibility that Leqembi’s fixed schedule does not. For someone working full-time or managing multiple medical appointments, this difference in frequency can meaningfully affect treatment adherence. Both drugs are administered intravenously and require specialized infusion center infrastructure, so neither offers the convenience of an oral medication. However, the spacing between visits differs substantially enough to affect real-world patient compliance and quality of life during the treatment period.
What Is the Complete Treatment Timeline and Monitoring Duration?
Leqembi’s treatment course is clearly defined: 18 months of active infusions followed by ongoing monitoring. after the 18-month window concludes, patients stop receiving infusions but continue to need brain MRI scans at regular intervals to detect delayed ARIA effects. The total burden includes not just the infusion appointments but also baseline MRI before treatment starts and then multiple MRIs during and after the 18-month period—potentially every four to six months depending on imaging protocols and individual risk factors. Kisunla’s timeline is less rigidly defined by the clinical trial design. The approval was based on 18 months of data, similar to Leqembi, but the drug’s pharmacology may allow for longer-term use at lower maintenance doses.
Some patients may continue monthly infusions indefinitely if they tolerate the drug well, while others may stop after 18 months. The monitoring requirements are comparable to Leqembi’s—regular MRI scans throughout treatment and for some period afterward—but the flexible dosing schedule means individual timelines can vary considerably. A critical limitation: both drugs require amyloid positron emission tomography (PET) or advanced blood biomarkers to confirm amyloid pathology before treatment begins. This initial screening step is not a one-time event; repeat imaging may be needed if diagnosis is uncertain or if symptoms change during treatment. Insurance approval often hinges on documented amyloid positivity, meaning patients without clear biomarker evidence may face barriers to starting either drug regardless of their cognitive symptoms.
Understanding ARIA (Amyloid-Related Imaging Abnormalities) and Risk Profiles
ARIA encompasses two main types of imaging abnormalities: ARIA-E (brain edema or swelling) and ARIA-H (microhemorrhages or brain microinfarcts). Both occur because these anti-amyloid antibodies target amyloid plaques in the brain, and the immune response to clearing those plaques can occasionally damage the small blood vessels in the brain as a side effect. Neither drug eliminates this risk; the question is not whether ARIA can occur, but rather the likelihood and severity for an individual patient. Leqembi showed ARIA-E in roughly 12–17% of treated patients in clinical trials, with symptomatic swelling occurring in a smaller percentage. ARIA-H occurred in approximately 17–26% of patients, though many experienced asymptomatic microhemorrhages detected only on MRI rather than through symptoms.
Kisunla’s safety profile from its approval trial showed somewhat lower ARIA-E rates (around 11% symptomatic or asymptomatic) and comparable ARIA-H rates, though head-to-head trials have not been conducted, making direct comparisons uncertain. The most important warning: either drug can cause serious neurological symptoms if ARIA develops. Swelling can trigger headaches, confusion, vision changes, or seizures. Microhemorrhages rarely cause symptoms but occasionally lead to stroke-like events. Patients taking certain blood thinners or with uncontrolled high blood pressure face higher ARIA risk and may not be appropriate candidates for either drug. Before starting treatment, patients must understand that regular MRI scanning is not optional—it is essential for detecting asymptomatic ARIA before it becomes dangerous.
Who Is Eligible to Receive Each Drug and What Testing Is Required?
Both Leqembi and Kisunla are approved for patients with mild cognitive impairment (MCI) or mild dementia stage Alzheimer’s disease with confirmed amyloid pathology. This is a critical restriction: patients must have documented cognitive symptoms; asymptomatic individuals with amyloid on imaging do not qualify. Additionally, patients with moderate to severe dementia fall outside the approved indication for both drugs, meaning individuals who delay diagnosis or who develop symptoms undetected may miss the window when these drugs can help. Amyloid confirmation can occur through amyloid PET imaging or, more recently, through blood tests measuring phosphorylated tau (p-tau) and amyloid-beta ratios.
Blood testing is faster and less expensive than PET, but not all medical centers have access to these biomarker tests yet, and insurance coverage for blood biomarkers remains inconsistent. Kisunla’s approval documentation specifies that amyloid PET imaging was used in its trials, while Leqembi’s pathway has evolved to accept blood biomarkers more readily. This difference may affect which patients can access which drug depending on local testing availability. A practical comparison: a patient in a rural area without access to amyloid PET imaging may be able to pursue Leqembi via blood biomarkers but face barriers accessing Kisunla if their local system has not adopted the newer biomarker approaches. Geography and healthcare infrastructure can determine drug availability as much as clinical eligibility.
Managing Infusion Reactions and Required Safety Monitoring
Both drugs can trigger infusion-related reactions, ranging from mild (fever, chills, fatigue) to severe (hypersensitivity reactions requiring hospitalization). These reactions occur in a minority of patients but are serious enough to require patients to remain at the infusion center for observation for at least one hour after each dose. For Leqembi, this means 36 hours of total observation time across 18 months; for Kisunla, the number is lower during the maintenance phase. Regular brain MRI scanning is mandatory for both drugs, not optional.
The frequency varies but typically includes baseline imaging before treatment, then scans at set intervals (often every four to six months) throughout treatment and for at least six months to one year after infusions end. This means patients must be able to tolerate MRI scanning—individuals with claustrophobia, metallic implants, or severe anxiety may struggle with the monitoring requirements as much as with the infusions themselves. The major limitation many patients underestimate: symptom overlap between ARIA and disease progression can be confusing. If a patient develops new forgetfulness, confusion, or headaches during treatment, it becomes difficult to determine whether these represent normal Alzheimer’s progression, an ARIA event, or an unrelated medical issue. This diagnostic uncertainty is why frequent imaging becomes so important—the MRI can provide objective evidence of brain changes that clinical examination alone cannot.
Insurance, Cost, and Access Barriers in Practice
Both Leqembi and Kisunla are expensive medications, with annual treatment costs potentially exceeding $25,000 to $35,000 before insurance, though exact pricing and coverage vary significantly by insurer, geographic location, and whether the patient qualifies for manufacturer copay assistance programs. Medicare currently covers both drugs through Part B, but private insurance coverage remains variable, with some plans requiring prior authorization, documentation of amyloid status, cognitive testing results, and proof of cognitive decline over time.
A real-world example illustrates the access challenge: an 72-year-old patient with MCI and amyloid positivity may qualify clinically for Leqembi but encounter a six-week insurance authorization delay if their plan requires quarterly cognitive scores proving decline. Meanwhile, another patient at a different healthcare system might begin infusions within two weeks. These variations in access are not medical—they reflect insurance bureaucracy and regional differences in how quickly providers can complete required documentation.
Questions Every Patient Should Discuss With Their Doctor Before Starting Treatment
Before committing to either drug, patients should ask their neurologist or primary care physician: What is my ARIA risk based on my specific imaging, age, and medical history? Am I on any blood thinners or medications that interact with these drugs? What happens if I develop ARIA symptoms during treatment—how quickly can I access emergency evaluation? Can I safely pause or stop treatment if side effects become intolerable? Patients should also clarify the practical logistics: How frequently will I need MRIs, and are they scheduled in advance or on demand? If I miss an infusion appointment, can it be rescheduled, or does the treatment protocol reset? What is the clinic’s experience with the specific drug my doctor recommends—have other patients at this center received it, and what has their experience been? The answer to the last question can make the difference between smooth treatment and repeated infusion delays due to provider inexperience with the newer anti-amyloid monoclonal antibodies.
- —
